SecBot SecBot
SECBOTREPLAY Home › Report › LXRX

LXRX · Lexicon Pharmaceuticals reported Q4 and full-year 2025 financial…

Lexicon Pharmaceuticals, Inc. · PRESS-RELEASE filed Mar 5, 2026 at 06:59 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Mar 5, 2026 at 06:59 ET

Lexicon Pharmaceuticals reported Q4 and full-year 2025 financial results with significantly reduced net loss and lower operating expenses, driven by strategic repositioning. The company highlighted key pipeline progress, including sotagliflozin NDA resubmission plans for T1D and mid-2026 enrollment completion expected for the SONATA-HCM Phase 3 study. A $106.7M capital raise and milestone payment in February 2026 strengthened its cash position to over $220M.

  • Q4 2025 revenue was $5.5M (vs. $26.6M in Q4 2024), driven by $4.3M in licensing revenue and $1.1M in INPEFA net sales.
  • Full-year 2025 revenue was $49.8M (vs. $31.1M in 2024), primarily due to $45M upfront licensing payment from Novo Nordisk.
  • Net loss narrowed to $15.5M in Q4 2025 (vs. $33.8M in Q4 2024) and $50.3M for full-year 2025 (vs. $200.4M in 2024).
  • R&D and SG&A expenses declined sharply year-over-year due to reduced trial costs and strategic repositioning.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access